Ketamine Psychedelic Therapy Explained: From Onset to Outcome

The body of research about psychedelic treatments for mental health is expanding rapidly, and public interest and curiosity are growing by the day. Many people are exploring what these emerging treatments actually are, and which options are available now. 

While substances like psilocybin and MDMA are still largely in research or regulatory review, ketamine and Spravato (a ketamine derivative) are already being used in clinical settings today as safe, evidence-based treatments for several mental health conditions. Sometimes described as “psychedelic-adjacent,” ketamine can produce altered states of consciousness that may include perceptual, emotional, or introspective experiences associated with psychedelic therapies. At the same time, it works through a distinct neurological mechanism.

Is ketamine a psychedelic?

Ketamine is classified as a dissociative anesthetic, rather than a classic psychedelic. While it falls under the broader category of hallucinogenic substances, it works differently in the brain.

Classic psychedelics, such as LSD or psilocybin, primarily act on serotonin receptors and are known for producing intense sensory changes and altered perception. Ketamine, by contrast, acts on NMDA receptors and a brain chemical called glutamate. Ketamine leads to a dissociative state, often described as a sense of detachment from the body or environment.

This more dream-like, gentler experience may be better suited for patients who struggle with anxiety or have difficulty letting go of control. Classic psychedelics, by contrast, can produce more intense and emotionally challenging experiences, which may be more appropriate in other therapeutic contexts.

Although ketamine is pharmacologically distinct, it is sometimes grouped alongside psychedelics. Both can alter perception, mood, and consciousness and in therapeutic settings, both are used to support treatment for similar mental health conditions, including depression, PTSD, and anxiety. 

This is why ketamine is referred to as “psychedelic-adjacent.” The term describes substances that share certain mind-altering and therapeutic properties with classic psychedelics but differ in their underlying biology and subjective effects. Other psychedelic-adjacent drugs include ibogaine, dextromethorphan (DXM), nitrous oxide, and salvinorin A. 

Ketamine is one of the most prominent examples in this category. To date, its well-established medical use  and legal status have made it more accessible in clinical settings compared to many classic psychedelics.

What is ketamine psychedelic therapy?

Ketamine psychedelic therapy is the clinical use of ketamine within a structured, medically supervised treatment plan. Backed by an extensive body of scientific evidence, it’s designed to provide relief and healing for mental health disorders. 

In a clinical setting like Keta Medical Center, ketamine treatment follows a clear, structured process. Ketamine therapy is guided by medical professionals at every step.  First, doctors carefully screen patients to determine if they are appropriate candidates. From there, ketamine is administered in precise, controlled doses under medical supervision, with continuous monitoring throughout each session to ensure safety and comfort.

A key part of this approach is integration — the therapeutic work that ideally takes place between ketamine treatments, with the goal of lasting emotional recovery. Ketamine creates a neuroplastic window during which the brain is more adaptable; this is where therapy becomes particularly powerful. 

In ketamine-assisted psychotherapy (KAP), patients work with their therapist to process material that arises. This may include identifying negative patterns, reframing perspectives, embracing a healthier mindset and making meaningful behavioral changes. Integration sessions typically take place within 24–48 hours, helping patients make sense of the experience and incorporate new insights into their daily lives.

The combination of medical treatment, psychological support, and structured follow-up care define ketamine psychedelic therapy as a coordinated clinical process designed to produce real, sustained outcomes.

What does ketamine therapy feel like? 

Ketamine works differently for everyone and during every session. Most people find the experience pleasant, sometimes describing a floaty, deeply relaxed sensation, almost like being in a dream. Others may have a more intense or transcendent journey. Many experience dissociation, a temporary mental state in which a person feels detached from their surroundings or disconnected from their body. Visual experiences are also common and may include vivid colors, geometric patterns, dreamlike imagery, or surreal, shifting landscapes. 

For most patients, this altered state creates a space to process difficult emotions, memories, or thought patterns from a new and more manageable perspective. As the effects wear off, most patients gradually return to full awareness feeling calm, reflective, or mentally lighter.

Whether the altered state is subtle or vivid, ketamine’s effectiveness does not depend solely on the nature of the experience itself. The medicine is still working biologically, triggering a surge of glutamate and promoting the formation of new neural pathways that support healing and improved mental flexibility.

How ketamine works in the brain

Ketamine works differently from traditional antidepressants. Most medications target serotonin or norepinephrine and can take weeks to produce noticeable effects. Ketamine, by contrast, acts on a separate system in the brain. 

Ketamine targets glutamate, the brain’s most abundant neurotransmitter. The drug triggers a surge of glutamate, which helps restore communication between brain cells. This increased signaling is associated with rapid improvements in mood and cognitive function. 

At the same time, this process promotes neuroplasticity — the brain’s ability to “learn” by forming new neural connections. The temporary window of the brain’s increased ability to “rewire” helps to shift patterns of thought and emotional response. When paired with therapy, it is especially effective. 

Because of this mechanism, ketamine has been shown to produce rapid antidepressant effects, offering relief on a much faster timeline than many conventional treatments. Ketamine’s safety and effectiveness for treating depression and other mental health conditions are supported by an extensive and growing body of research. Thousands of scientific papers and hundreds of clinical trials have examined its impact.

What does the new federal focus on psychedelics mean for patients?

In April 2026, a federal Executive Order directed health agencies to accelerate research and approval of new mental health treatments, including psychedelic therapies like psilocybin. Psilocybin-based treatments for depression are already in late-stage research, with FDA review potentially beginning in late 2026 and possible approval expected as early as 2027.

However, these treatments are not yet approved or widely available nationwide. The Executive Order supports faster research and review. It does not make substances like psilocybin or ibogaine legal for general medical use today. 

What is available now are established, legal options like ketamine therapy, which is already used in clinical settings under medical supervision. As research progresses, more treatments may become available. For now, ketamine remains one of the few accessible, evidence-based options.

Ketamine vs other psychedelic therapies

Recent federal efforts are speeding up research into psychedelic substances such as psilocybin, MDMA, and ibogaine. Psilocybin is a naturally occurring compound found in certain mushrooms. It is currently being studied as a treatment for depression and other mental health conditions. MDMA is a synthetic compound that primarily affects mood and emotional processing, with ongoing research in PTSD treatment. Ibogaine is a plant-derived psychoactive substance that is being explored for substance use disorders, though research remains in early stages. While these are still in development, ketamine has been used clinically for treating mental health conditions for more than twenty years now.